var data={"title":"Palonosetron: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Palonosetron: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6716?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=palonosetron-patient-drug-information\" class=\"drug drug_patient\">see &quot;Palonosetron: Patient drug information&quot;</a> and <a href=\"topic.htm?path=palonosetron-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Palonosetron: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14877561\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aloxi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50297423\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aloxi</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205861\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiemetic;</li>\n      <li>\n        Selective 5-HT<sub>3</sub> Receptor Antagonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205844\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of chemotherapy-induced nausea and vomiting (moderately and highly emetogenic chemotherapy):</b> IV: 0.25 mg beginning ~30 minutes prior to the start of chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule [Canadian product]: Moderately emetogenic chemotherapy: Oral: 0.5 mg ~1 hour prior to the start of chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Guideline recommendations: </i></b>\n      <b>Prevention of chemotherapy-induced nausea and vomiting: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>American Society of Clinical Oncology (ASCO [Hesketh 2017]): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High emetic risk, including most anthracyclines combined with cyclophosphamide regimens; antiemetic regimen also includes dexamethasone (days 1 to 4), an NK<sub>1</sub> receptor antagonist, and olanzapine (days 1 to 4):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 0.25 mg on day 1 prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 0.5 mg [Canadian product] on day 1 prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate emetic risk; antiemetic regimen also includes dexamethasone (days 1 to 3) [and an NK<sub>1</sub> receptor antagonist for carboplatin AUC &ge;4]:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 0.25 mg on day 1 prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 0.5 mg [Canadian product] on day 1 prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low emetic risk:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 0.25 mg prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 0.5 mg [Canadian product] prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Multinational Association of Supportive Care in Cancer (MASCC) and European Society of Medical Oncology (ESMO) (Roila 2016): </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Highly emetic chemotherapy, (antiemetic regimen includes dexamethasone and aprepitant/fosaprepitant/rolapitant):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 0.25 mg on day 1 prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 0.5 mg [Canadian product] on day 1 prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderately emetic chemotherapy (antiemetic regimen includes dexamethasone [and aprepitant/fosaprepitant/rolapitant for AC chemotherapy regimen]):</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">IV: 0.25 mg on day 1 prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 0.5 mg [Canadian product] on day 1 prior to chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Low emetic risk: 0.25 mg IV or 0.5 mg orally [Canadian product] prior to chemotherapy on day 1 may be considered</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of postoperative nausea and vomiting:</b> IV: 0.075 mg immediately prior to anesthesia induction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25120798\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=palonosetron-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Palonosetron: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of chemotherapy-induced nausea and vomiting (highly emetogenic chemotherapy): </b>Infants &ge;1 month, Children, and Adolescents &lt;17 years: IV: 20 <b>mcg</b>/kg (maximum dose: 1.5 <b>mg</b>) beginning ~30 minutes prior to the start of chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Pediatric guideline recommendations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of chemotherapy-induced nausea and vomiting for highly emetogenic chemotherapy (Patel 2017):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;1 month to 6 months: IV: 20 <b>mcg</b>/kg once prior to chemotherapy (maximum: 1.5 <b>mg</b>/dose). Antiemetic regimen also includes dexamethasone (if no contraindications to corticosteroids).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;6 months, Children and Adolescents &lt;17 years: IV: 20 <b>mcg</b>/kg once prior to chemotherapy (maximum: 1.5 <b>mg</b>/dose). Antiemetic regimen also includes aprepitant (if <b>no</b> potential drug interactions) and dexamethasone (if no contraindications to corticosteroids).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;17 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 0.25 mg once prior to chemotherapy. Antiemetic regimen also includes aprepitant (if <b>no</b> potential drug interactions) and dexamethasone (if no contraindications to corticosteroids).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral [Canadian product]: 0.5 mg once prior to chemotherapy. Antiemetic regimen also includes aprepitant (if <b>no</b> potential drug interactions) and dexamethasone (if no contraindications to corticosteroids).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prevention of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy (off-label; Patel 2017):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;1 month to 6 months: IV: 20 <b>mcg</b>/kg once prior to chemotherapy (maximum: 1.5 <b>mg</b>/dose. Antiemetic regimen also includes dexamethasone (if no contraindications to corticosteroids).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;6 months, Children and Adolescents &lt;17 years: IV: 20 <b>mcg</b>/kg once prior to chemotherapy (maximum: 1.5 <b>mg</b>/dose). Antiemetic regimen also includes dexamethasone; if patient cannot receive corticosteroids, antiemetic regimen may include aprepitant (if <b>no</b> potential drug interactions).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;17 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 0.25 mg once prior to chemotherapy. Antiemetic regimen also includes dexamethasone; if patient cannot receive corticosteroids, antiemetic regimen may include aprepitant (if <b>no</b> potential drug interactions).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral [Canadian product]: 0.5 mg once prior to chemotherapy. Antiemetic regimen also includes dexamethasone; if patient cannot receive corticosteroids, antiemetic regimen may include aprepitant (if <b>no</b> potential drug interactions).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205845\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary. Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205846\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment is necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205847\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment is necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205824\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aloxi: 0.25 mg/5 mL (5 mL) [contains edetate disodium]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205812\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50338489\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aloxi: 0.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205826\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Flush IV line with NS prior to and following administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prevention of chemotherapy-induced nausea and vomiting:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: Infuse over 15 minutes, beginning ~30 minutes prior to the start of chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Infuse over 30 seconds, beginning ~30 minutes prior to the start of chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsule [Canadian product]: May be administered with or without food.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prevention of postoperative nausea and vomiting: Infuse over 10 seconds immediately prior to anesthesia induction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205825\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Chemotherapy-induced nausea and vomiting:</b> Prevention of acute and delayed nausea and vomiting associated with initial and repeat courses in patients treated with moderately emetogenic cancer chemotherapy in adults; prevention of acute nausea and vomiting associated with initial and repeat courses in patients treated with highly emetogenic cancer chemotherapy in adults; prevention of acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy (including highly emetogenic chemotherapy) in pediatric patients 1 month to &lt;17 years.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capsules [Canadian product]: Prevention of acute nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Postoperative nausea and vomiting:</b> Prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Limitations of use: Routine prophylaxis for PONV in patients with minimal expectation of nausea and/or vomiting is not recommended, although use is recommended in patients when nausea and vomiting must be avoided in the postoperative period, even if the incidence of PONV is low.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50338517\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Chemotherapy-induced nausea and vomiting, moderately emetogenic chemotherapy (pediatrics)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205868\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aloxi may be confused with Eloxatin, oxaliplatin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Palonosetron may be confused with dolasetron, granisetron, ondansetron</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205817\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequencies reported for both indications (chemotherapy-associated nausea and vomiting and postoperative nausea and vomiting) and in adults unless otherwise noted. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Prolonged Q-T interval on ECG (PONV 1% to 5%; chemotherapy-associated &lt;1%), bradycardia (chemotherapy-associated 1%), sinus bradycardia (PONV: 1%), tachycardia (may be nonsustained; 1%), hypotension (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (chemotherapy-associated: Adults 9%; infants, children, and adolescents &lt;1%), anxiety (chemotherapy-associated: 1%), dizziness (infants, children, adolescents, and adults &le;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Pruritus (PONV: 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hyperkalemia (chemotherapy-associated: 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Constipation (chemotherapy-associated: 5%), diarrhea (&le;1%), flatulence (&le;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Urinary retention (&le;1%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic: Increased serum ALT (&le;1%; may be transient), increased serum AST (&le;1%; may be transient) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Weakness (chemotherapy-associated: 1%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abdominal pain, allergic dermatitis, amblyopia, anaphylactic shock (very rare), anaphylaxis (very rare), anasarca, anemia, anorexia, arthralgia, cardiac arrhythmia, chills, decreased appetite, decreased blood pressure, decreased gastrointestinal motility, decreased platelet count, dermatological disease (infants, children, and adolescents), distended vein, drowsiness, dyskinesia (infants, children, and adolescents), dyspepsia, electrolyte disturbance, epistaxis, erythema, euphoria, extrasystoles, eye irritation, fatigue, fever, flattened T wave on ECG, flu-like symptoms, glycosuria, hiccups, hot flash, hyperglycemia, hypersensitivity (very rare), hypersomnia, hypertension, hypokalemia, hypoventilation, increased bilirubin (transient), increased liver enzymes, infusion site pain (infants, children, and adolescents), injection site reaction (very rare; includes burning sensation at injection site, discomfort at injection site, induration at injection site, pain at injection site), insomnia, ischemic heart disease, laryngospasm, limb pain, metabolic acidosis, motion sickness, paresthesia, serotonin syndrome, sialorrhea, sinus arrhythmia, sinus tachycardia, skin rash, supraventricular extrasystole, tinnitus, vein discoloration, ventricular premature contractions, xerostomia </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205829\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Known hypersensitivity to palonosetron or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205815\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ECG effects: Selective 5-HT<sub>3</sub> receptor antagonists have been associated with dose-dependent increases in ECG intervals (eg, PR, QRS duration, QT/QTc, JT). A thorough QT/QTc study evaluating the effect of palonosetron on QT/QTc demonstrated a magnitude of effect less than the threshold for regulatory concern (Morganroth 2016). Reduction in heart rate may occur with the 5-HT<sub>3</sub> antagonists, including palonosetron (Gonullu 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity (including anaphylaxis) has been reported in patients with or without known hypersensitivity to other 5-HT<sub>3</sub> receptor antagonists.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Serotonin syndrome has been reported with 5-HT<sub>3</sub> receptor antagonists, predominantly when used in combination with other serotonergic agents (eg, SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, and/or methylene blue). Some of the cases have been fatal. The majority of serotonin syndrome reports due to 5-HT<sub>3</sub> receptor antagonists have occurred in a post-anesthesia setting or in an infusion center. Serotonin syndrome has also been reported following overdose of another 5-HT<sub>3</sub> receptor antagonist. Monitor patients for signs of serotonin syndrome, including mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis, dizziness, flushing, hyperthermia); neuromuscular changes (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination); gastrointestinal symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. If serotonin syndrome occurs, discontinue 5-HT<sub>3</sub> receptor antagonist treatment and begin supportive management.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chemotherapy-associated emesis: Antiemetics are most effective when used prophylactically (Roila 2016). If emesis occurs despite optimal antiemetic prophylaxis, re-evaluate emetic risk, disease, concurrent morbidities and medications to assure antiemetic regimen is optimized (Hesketh 2017).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Postoperative nausea and vomiting: Use is not recommended if there is little expectation of postoperative nausea and vomiting (PONV); may use for low expectation of PONV if it is essential to avoid nausea and vomiting in the postoperative period.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205854\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205819\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9944&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Antiemetics (5HT3 Antagonists) may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205821\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205831\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies. Use during pregnancy only if clearly needed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205832\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if palonosetron is present in breast milk. Due to the potential for adverse reactions in the breastfed infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue palonosetron, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205814\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Palonosetron is a selective 5-HT<sub>3</sub> receptor antagonist, blocking serotonin, both on vagal nerve terminals in the periphery and centrally in the chemoreceptor trigger zone</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F205828\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Capsules [Canadian product]: Well absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 1 month to 17 years: Mean range: 5.3 to 6.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 8.3 &plusmn; 2.5 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~62%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: ~50% metabolized via CYP enzymes (and likely other pathways) to relatively inactive metabolites (N-oxide-palonosetron and 6-S-hydroxy-palonosetron); CYP1A2, 2D6, and 3A4 contribute to its metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Capsules [Canadian product]: 97%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: IV: Children 1 month to 17 years: Median: 29.5 hours (range: 20 to 30 hours); Adults: ~40 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak (plasma): Capsules [Canadian product]: 5.1 &plusmn; 5.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (80%; 40% as unchanged drug)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and children &lt;2 years: 0.31 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 2 to &lt;12 years: Mean range: 0.19 to 0.23 L/hour/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years, Adolescents, and Adults: 0.16 L/hour/kg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5062442\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aloxi Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/5 mL (5 mL): $543.60</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5539911\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aloxi (AT, AU, BB, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HK, HR, HU, IE, IS, IT, JP, KR, LT, LU, LV, MT, MY, NL, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, TH, TR, TW, VN);</li>\n      <li>Avonil (BD);</li>\n      <li>Lowvo (CN);</li>\n      <li>Onicit (AR, BR, CL, CO, CR, DO, EC, GT, HN, MX, NI, PA, PE, SV, VE);</li>\n      <li>Palnox (BD);</li>\n      <li>Palorex (BD);</li>\n      <li>Paloxi (BD, ID, IL, KR);</li>\n      <li>Paloxiron (BD);</li>\n      <li>Palzen (IN);</li>\n      <li>Zhiruo (CN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Aapro MS, Grunberg SM, Manikhas GM, et al, &ldquo;A Phase III, Double-Blind, Randomized Trial of Palonosetron Compared With Ondansetron in Preventing Chemotherapy-Induced Nausea and Vomiting Following Highly Emetogenic Chemotherapy,&rdquo; <i>Ann Oncol</i>, 2006, 17(9):1441-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/16766588/pubmed\" target=\"_blank\" id=\"16766588\">16766588</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aloxi (palonosetron) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; December 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aloxi (palonosetron) [product monograph]. Pickering, Ontario, Canada: Perdue Pharma; May, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gonullu G, Demircan S, Demirag MK, et al. Electrocardiographic findings of palonosetron in cancer patients. <i>Support Care Cancer</i>. 2012;20(7):1435-1439.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/21773677/pubmed\" target=\"_blank\" id=\"21773677\">21773677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gralla R, Lichinister M, Van Der Vegt S, et al, &ldquo;Palonosetron Improves Prevention of Chemotherapy-Induced Nausea and Vomiting Following Moderately Emetogenic Chemotherapy: Results of a Double-Blind Randomized Phase III Trial Comparing Single Doses of Palonosetron With Ondansetron,&rdquo; <i>Ann Oncol</i>, 2003, 14(10):1570-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/14504060/pubmed\" target=\"_blank\" id=\"14504060\">14504060</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kupiec TC, Trusley C, Ben M, et al, &ldquo;Physical and Chemical Stability of Palonosetron Hydrochloride With Five Common Parenteral Drugs During Simulated Y-Site Administration,&rdquo; <i>Am J Health-Syst Pharm</i>, 2008, 65(18):1735-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/18769000/pubmed\" target=\"_blank\" id=\"18769000\">18769000</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morganroth J, Flaharty KK, Parisi S, et al. Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers. <i>Support Care Cancer</i>. 2016;24(2):621-627.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/26111957/pubmed\" target=\"_blank\" id=\"26111957\">26111957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Palonosetron hydrochloride [prescribing information]. Lake Zurich, IL: Fresenius Kabi; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Patel P, Robinson PD, Thackray J, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update [published online April 28, 2017]. <i>Pediatr Blood Cancer</i>. 2017.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/28453189/pubmed\" target=\"_blank\" id=\"28453189\">28453189</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(Suppl 5):S119-S133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tang J, D'Angelo R, White PF, et al, &ldquo;The Efficacy of RS-25259, A Long-Acting Selective 5-HT<sub>3</sub> Receptor Antagonist, for Preventing Postoperative Nausea and Vomiting After Hysterectomy Procedures,&rdquo; <i>Anesth Analg</i>, 1998, 87(2):462-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/9706951/pubmed\" target=\"_blank\" id=\"9706951\">9706951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trissel LA and Xu QA, &ldquo;Physical and Chemical Stability of Palonosetron HCl in 4 Infusion Solutions,&rdquo; <i>Ann Pharmacother</i>, 2004a, 38(10):1608-11.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/15328393/pubmed\" target=\"_blank\" id=\"15328393\">15328393</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zambelli A, Sagrada P, and Pavesi L, &ldquo;Seizure Associated With Palonosetron,&rdquo; <i>Support Care Cancer</i>, 2009, 17(3):217.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/palonosetron-drug-information/abstract-text/19139929/pubmed\" target=\"_blank\" id=\"19139929\">19139929</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9944 Version 116.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F14877561\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F50297423\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F205861\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F205844\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F25120798\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F205845\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F205846\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F205847\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F205824\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F205812\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F50338489\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F205826\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F205825\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F50338517\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F205868\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F205817\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F205829\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F205815\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F205854\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F205819\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F205821\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F205831\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F205832\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F205814\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F205828\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5062442\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F5539911\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9944|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=palonosetron-patient-drug-information\" class=\"drug drug_patient\">Palonosetron: Patient drug information</a></li><li><a href=\"topic.htm?path=palonosetron-pediatric-drug-information\" class=\"drug drug_pediatric\">Palonosetron: Pediatric drug information</a></li></ul></div></div>","javascript":null}